Global mRNA expression profiles, IL2RA and STAT3 expression, and changes of CTCL-related pathway, bio-function, and network activation after antibiotic therapy. (A) Heatmap and 2-way unsupervised hierarchical clustering based on the 1463 differentially expressed genes (1196 up- and 267 downregulated, more than twofold change, P < .05, q = 0.10) between lesional (patients 1-8) and skin from healthy controls (HC 1-6) before antibiotic treatment (day 0). Top row, the subject identification (8 patients and 6 HCs). The second from top row shows the time of sampling: before (0 d), 10 days (10 d), 1 month (1 m), and 2 months (2 m) after treatment. The healthy skin samples cluster to the right, and together with samples from patient 5-2m, patient 7-10d, patient 6-10d, and patient 6-1m, indicate partial normalization of the CTCL signature posttreatment. Gene expression values have been z scaled (mean = 0, var = 1) and are indicated in the heatmap as yellow (upregulated) or blue (downregulated). (B) RT-qPCR of the IL2RA and STAT3 expression in all patients before antibiotic treatment and at 10 days, 1 month, and 2 months, and in 6 HC. (C) Upstream analysis of IL-2 signaling and STAT3 activation, and bio-function activation z scores for neoplasia, proliferation, and inflammation before and 10 days, 1 month, and 2 months after treatment. (D) Activation of CTCL-involved signaling before and 10 days, 1 month, and 2 months after antibiotic treatment. The contrasts shown are CTCL vs HC at day 0 (CTCL/HC D0), and CTCL at 10 days, 1 month, and 2 months vs day 0 (paired analysis, CTCL D10-1m-2m/D0).